IQVIA Holdings Inc. (IQV)
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
- Symbol
- IQV
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $43.10B
- 52 week range
- 154.5 - 277.4
Valuation
- Share price
- $258.21 (close of 2026-10-02)
- P/E (TTM)
- 31.80x
- Price to book
- 6.79x
- Price to free cash flow
- 20.37x
- Enterprise value
- $57.21B
- Book value per share
- $38.04
Price performance
| Period | Change |
|---|---|
| 1 day | -0.96% |
| 5 days | -4.50% |
| 1 month | -2.13% |
| 3 months | +24.72% |
| 6 months | +49.03% |
| Year to date | +14.55% |
| 1 year | +26.36% |
| 3 years | +33.18% |
| 5 years | +6.90% |
| 10 years | +218.54% |
| All time | +513.18% |
Members of Congress who disclosed IQV trades
Kevin Hern · Robert Bresnahan · Markwayne Mullin · John Boozman
Super investors holding IQV
Bill Nygren (Harris Associates LP) · Greenhaven Associates (Greenhaven Associates Inc) · Vulcan Value Partners (Vulcan Value Partners, LLC) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- 20.51%
- Return on invested capital
- 9.37%
- Return on assets
- 4.54%
- Return on capital employed
- 10.10%
- Gross margin
- 25.63%
- Net margin
- 8.34%
- EBITDA margin
- 20.39%
- Revenue growth
- 5.87%
- Net income growth
- -0.95%
- Free cash flow growth
- -2.98%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 4.91%
- Current ratio
- 0.75x
- Net debt to EBITDA
- 4.01x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $16.31B
- Cost of revenue
- $12.13B
- Gross profit
- $4.18B
- EBITDA
- $3.33B
- Net income
- $1.36B
- Earnings per share
- $7.91
- Interest expense
- $729.00M
- Shares outstanding
- 171.90M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $16.31B | $4.18B | $1.36B | $7.91 |
| 2024-12-31 | $15.40B | $4.19B | $1.37B | $7.57 |
| 2023-12-31 | $14.98B | $4.03B | $1.36B | $7.39 |
| 2022-12-31 | $14.41B | $3.87B | $1.09B | $5.82 |
| 2021-12-31 | $13.87B | $3.36B | $966.00M | $5.05 |
| 2020-12-31 | $11.36B | $2.52B | $279.00M | $1.46 |
| 2019-12-31 | $11.09B | $2.51B | $191.00M | $0.98 |
| 2018-12-31 | $10.41B | $3.67B | $259.00M | $1.27 |
| 2017-12-31 | $9.70B | $5.08B | $1.28B | $5.86 |
| 2016-12-31 | $6.82B | $3.58B | $72.00M | $0.48 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 25.63% | 8.34% | 20.51% | 9.37% |
| 2024-12-31 | 27.22% | 8.91% | 22.63% | 10.26% |
| 2023-12-31 | 26.90% | 9.06% | 22.22% | 10.07% |
| 2022-12-31 | 26.86% | 7.57% | 18.92% | 8.76% |
| 2021-12-31 | 24.20% | 6.96% | 15.99% | 7.05% |
| 2020-12-31 | 22.19% | 2.46% | 4.44% | 3.73% |
| 2019-12-31 | 22.65% | 1.72% | 3.05% | 3.75% |
| 2018-12-31 | 35.21% | 2.49% | 3.72% | 4.00% |
| 2017-12-31 | 52.36% | 13.16% | 15.49% | 3.81% |
| 2016-12-31 | 52.52% | 1.06% | 0.82% | 1.95% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $1.98B | $13.88B |
| 2024-12-31 | $1.70B | $12.84B |
| 2023-12-31 | $1.38B | $12.96B |
| 2022-12-31 | $1.22B | $12.60B |
| 2021-12-31 | $1.37B | $12.03B |
| 2020-12-31 | $1.81B | $12.38B |
| 2019-12-31 | $837.00M | $11.54B |
| 2018-12-31 | $891.00M | $10.91B |
| 2017-12-31 | $1.00B | $10.12B |
| 2016-12-31 | $1.24B | $7.11B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $2.05B | $247.00M |
| 2024-12-31 | $2.11B | $206.00M |
| 2023-12-31 | $1.50B | $217.00M |
| 2022-12-31 | $1.59B | $194.00M |
| 2021-12-31 | $2.30B | $170.00M |
| 2020-12-31 | $1.34B | $95.00M |
| 2019-12-31 | $835.00M | $146.00M |
| 2018-12-31 | $795.00M | $113.00M |
| 2017-12-31 | $601.00M | $106.00M |
| 2016-12-31 | $696.00M | $106.00M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-27
- Consensus EPS estimate
- $2.95
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-28 | Jun/2026 | $2.72 |
| 2026-05-05 | Mar/2026 | $2.51 |
| 2026-02-05 | Dec/2025 | $3.13 |
| 2025-10-28 | Sep/2025 | $2.68 |
| 2025-07-22 | Jun/2025 | $2.50 |
| 2025-05-06 | Mar/2025 | $2.38 |
| 2025-02-06 | Dec/2024 | $2.86 |
| 2024-10-31 | Sep/2024 | $2.57 |
Filings and sources
- Company website
- iqvia.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Waters Corp (WAT) · Agilent Technologies, Inc. (A) · IDEXX Laboratories Inc (IDXX) · Natera, Inc. (NTRA) · Illumina, Inc. (ILMN) · Danaher Corp (DHR) · Mettler-Toledo International Inc (MTD) · Thermo Fisher Scientific Inc. (TMO)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades